의약품 제조 설비 시장 규모, 점유율, 성장 및 세계 산업 분석 : 유형별 및 용도별, 지역별 인사이트와 예측(2026-2034년)

Growth Factors of pharmaceutical manufacturing equipment Market

The global pharmaceutical manufacturing equipment market is witnessing steady expansion driven by rising medicine demand, rapid technological advancements, and increasingly stringent regulatory frameworks. In 2025, the market was valued at USD 23.67 billion. According to the report, it is projected to grow from USD 25.14 billion in 2026 to USD 46.21 billion by 2034, registering a compound annual growth rate (CAGR) of 7.9% during the forecast period (2026-2034). The Asia Pacific region dominated the global market in 2025, accounting for 42.1% of the total share.

The market operates in a highly competitive environment where efficiency, regulatory compliance, and technological innovation play decisive roles. Rising investments in biopharmaceuticals, precision medicine, and high-tech manufacturing solutions are significantly improving production efficiency and compliance adherence. Additionally, geopolitical developments, global trade dynamics, and evolving Environmental, Social, and Governance (ESG) policies are influencing long-term market expansion.

Impact of IoT and Automation

The integration of Internet of Things (IoT) and automation technologies has transformed pharmaceutical manufacturing by improving quality control, operational efficiency, and regulatory compliance. The COVID-19 pandemic accelerated digital transformation, particularly increasing demand for high-speed and flexible manufacturing systems for vaccines and therapeutics.

IoT-enabled equipment supports real-time monitoring, predictive maintenance, and data-driven decision-making, while automation reduces labor dependency and minimizes errors. These advancements are driving investments in adaptable manufacturing solutions capable of responding swiftly to fluctuating therapeutic demand. For instance, in October 2024, Korber and AspenTech partnered to integrate PAS-X MES with AspenTech Inmation, enabling seamless shopfloor integration and advanced data management for pharmaceutical manufacturers.

Pharmaceutical Manufacturing Equipment Market Trends

One of the most prominent trends shaping the market is the rapid adoption of continuous manufacturing, which reduces production time, enhances efficiency, and lowers operational costs. Additionally, Single-Use Technologies (SUT) are gaining traction due to their ability to minimize contamination risks and reduce cleaning and validation requirements.

Advanced anti-counterfeiting technologies, including sterilization systems and track-and-trace solutions, are also gaining importance. Manufacturers are increasingly focusing on equipment designed for continuous and flexible manufacturing environments, aligning with evolving regulatory and operational requirements. In June 2024, GEA Group introduced the first single-use disc centrifuge for perfusion, supporting high-intensity continuous cell separation.

Market Dynamics

Market Drivers:

Growth is driven by rising demand for generic drugs, biologics, and Active Pharmaceutical Ingredients (API). Regulatory requirements set by authorities such as the FDA and EMA necessitate advanced precision equipment. Increased outsourcing to contract manufacturing organizations (CMOs and CDMOs) and growing adoption of Industry 4.0 technologies further support market expansion.

Market Restraints:

High capital investment remains a significant barrier, particularly for small and mid-sized manufacturers. Complex validation processes, regulatory compliance costs, and supply chain disruptions caused by geopolitical instability also pose challenges to market growth.

Market Opportunities:

The growing focus on sustainable and green manufacturing technologies presents major opportunities. Energy-efficient, waste-reducing equipment and expansion into emerging markets with limited advanced manufacturing infrastructure are expected to support long-term growth.

Segmentation Analysis

By equipment type, the dryer and granulator segment holds the largest market share due to its critical role in advanced formulation processes. Mixing and blending equipment is expected to witness the fastest growth, holding 22.79% market share in 2026.

By manufacturing type, continuous manufacturing is the fastest-growing segment, projected to grow at a CAGR of 8.27%, while batch processing is expected to dominate with 58.23% market share in 2026.

By end user, the CDMO segment leads the market, driven by extensive outsourcing and cost efficiency, and is expected to grow at a CAGR of 8.02%.

Regional Outlook

In 2025, Asia Pacific led the market with a value of USD 9.97 billion, increasing to USD 10.71 billion in 2026. China is expected to reach USD 4.36 billion in 2026, while India and Japan are projected at USD 2.45 billion and USD 1.45 billion, respectively.

North America is expected to reach USD 7.78 billion in 2026, followed by Europe at USD 4.15 billion. The Middle East & Africa is projected to reach USD 1.42 billion in 2026, supported by expanding healthcare infrastructure.

Conclusion

In conclusion, the pharmaceutical manufacturing equipment market is poised for sustained growth, expanding from USD 23.67 billion in 2025 to USD 46.21 billion by 2034. The convergence of automation, IoT, continuous manufacturing, and sustainable technologies is reshaping pharmaceutical production globally. Despite challenges such as high capital investment and regulatory complexities, strong demand for advanced medicines, API manufacturing, and outsourcing services ensures a positive long-term outlook for the market.

Segmentation By Equipment

• Mixing & Blending
• Milling
• Dryer & Granulators
• Extrusion
• Filling & Compression
• Inspection & Sterilization
• Packaging, etc.

By Manufacturing Type

• Continuous
• Batch

By End User

• Large Scale Pharma
• CDMO
• CMO
• CRO

By Region

• North America (By Equipment, By Manufacturing Type, By End User, and By Country)
  • U.S. (By End User)
  • Canada (By End User)
  • Mexico (By End User)
• Europe (By Equipment, By End User, and By Country)
  • U.K. (By End User)
  • Germany (By End User)
  • France (By End User)
  • Italy (By End User)
  • Switzerland (By End User)
  • Spain (By End User)
  • Rest of Europe
• Asia Pacific (By Equipment, By End User, and By Country)
  • China (By End User)
  • India (By End User)
  • Japan (By End User)
  • South Korea (By End User)
  • ASEAN (By End User)
  • Rest of Asia Pacific
• Middle East & Africa (By Equipment, By End User, and By Country)
  • South Africa (By End User)
  • GCC (By End User)
  • Rest of Middle East & Africa
• South America (By Equipment, By End User, and By Country)
  • Brazil (By End User)
  • Argentina (By End User)
  • Rest of South America

Key Market Players Profiled in the Report GEA Group AG (Germany), Syntegon Technology GmbH (Germany), Sartorius AG (Germany), ACG (India), IMA Group (Italy), Glatt GmbH (Germany), Romaco Group (Germany), Fette Compacting (Germany), Paul Mueller (U.S.), SED Pharma (China), etc.

Table of Content

1. Introduction

• 1.1. Definition, By Segment
• 1.2. Research Methodology/Approach
• 1.3. Data Sources

2. Executive Summary

3. Market Dynamics

• 3.1. Macro and Micro Economic Indicators
• 3.2. Drivers, Restraints, Opportunities and Trends
• 3.3. Impact of IoT and Automation

4. Competition Landscape

• 4.1. Business Strategies Adopted by Key Players
• 4.2. Consolidated SWOT Analysis of Key Players
• 4.3. Global Pharmaceutical Manufacturing Equipment Key Players [Top 3-5] Market Share/Ranking, 2025

5. Global Pharmaceutical Manufacturing Equipment Market Size Estimates and Forecasts, By Segments, 2021-2034

• 5.1. Key Findings
• 5.2. By Equipment (USD)
  • 5.2.1. Mixing & Blending
  • 5.2.2. Milling
  • 5.2.3. Dryer & Granulators
  • 5.2.4. Extrusion
  • 5.2.5. Filling & Compression
  • 5.2.6. Inspection & Sterilization
  • 5.2.7. Packaging, etc.
• 5.3. By Manufacturing Type (USD)
  • 5.3.1. Continuous
  • 5.3.2. Batch
• 5.4. By End User (USD)
  • 5.4.1. Large Scale Pharmas
  • 5.4.2. CDMO
  • 5.4.3. CMO
  • 5.4.4. CRO
• 5.5. By Region (USD)
  • 5.5.1. North America
  • 5.5.2. South America
  • 5.5.3. Europe
  • 5.5.4. Asia Pacific
  • 5.5.5. Middle East & Africa

6. North America Pharmaceutical Manufacturing Equipment Market Size Estimates and Forecasts, By Segments, 2021-2034

• 6.1. Key Findings
• 6.2. By Equipment (USD)
  • 6.2.1. Mixing & Blending
  • 6.2.2. Milling
  • 6.2.3. Dryer & Granulators
  • 6.2.4. Extrusion
  • 6.2.5. Filling & Compression
  • 6.2.6. Inspection & Sterilization
  • 6.2.7. Packaging, etc.
• 6.3. By Manufacturing Type (USD)
  • 6.3.1. Continuous
  • 6.3.2. Batch
• 6.4. By End User (USD)
  • 6.4.1. Large Scale Pharmas
  • 6.4.2. CDMO
  • 6.4.3. CMO
  • 6.4.4. CRO
• 6.5. By Country (USD)
  • 6.5.1. United States
    • 6.5.1.1. By End User
  • 6.5.2. Canada
    • 6.5.2.1. By End User
  • 6.5.3. Mexico
    • 6.5.3.1. By End User

7. South America Pharmaceutical Manufacturing Equipment Market Size Estimates and Forecasts, By Segments, 2021-2034

• 7.1. Key Findings
• 7.2. By Equipment (USD)
  • 7.2.1. Mixing & Blending
  • 7.2.2. Milling
  • 7.2.3. Dryer & Granulators
  • 7.2.4. Extrusion
  • 7.2.5. Filling & Compression
  • 7.2.6. Inspection & Sterilization
  • 7.2.7. Packaging, etc.
• 7.3. By Manufacturing Type (USD)
  • 7.3.1. Continuous
  • 7.3.2. Batch
• 7.4. By End User (USD)
  • 7.4.1. Large Scale Pharmas
  • 7.4.2. CDMO
  • 7.4.3. CMO
  • 7.4.4. CRO
• 7.5. By Country (USD)
  • 7.5.1. Brazil
    • 7.5.1.1. By End User
  • 7.5.2. Argentina
    • 7.5.2.1. By End User
  • 7.5.3. Rest of South America

8. Europe Pharmaceutical Manufacturing Equipment Market Size Estimates and Forecasts, By Segments, 2021-2034

• 8.1. Key Findings
• 8.2. By Equipment (USD)
  • 8.2.1. Mixing & Blending
  • 8.2.2. Milling
  • 8.2.3. Dryer & Granulators
  • 8.2.4. Extrusion
  • 8.2.5. Filling & Compression
  • 8.2.6. Inspection & Sterilization
  • 8.2.7. Packaging, etc.
• 8.3. By Manufacturing Type (USD)
  • 8.3.1. Continuous
  • 8.3.2. Batch
• 8.4. By End User (USD)
  • 8.4.1. Large Scale Pharmas
  • 8.4.2. CDMO
  • 8.4.3. CMO
  • 8.4.4. CRO
• 8.5. By Country (USD)
  • 8.5.1. United Kingdom
    • 8.5.1.1. By End User
  • 8.5.2. Germany
    • 8.5.2.1. By End User
  • 8.5.3. France
    • 8.5.3.1. By End User
  • 8.5.4. Italy
    • 8.5.4.1. By End User
  • 8.5.5. Switzerland
    • 8.5.5.1. By End User
  • 8.5.6. Spain
    • 8.5.6.1. By End User
  • 8.5.7. Rest of Europe

9. Asia Pacific Pharmaceutical Manufacturing Equipment Market Size Estimates and Forecasts, By Segments, 2021-2034

• 9.1. Key Findings
• 9.2. By Equipment (USD)
  • 9.2.1. Mixing & Blending
  • 9.2.2. Milling
  • 9.2.3. Dryer & Granulators
  • 9.2.4. Extrusion
  • 9.2.5. Filling & Compression
  • 9.2.6. Inspection & Sterilization
  • 9.2.7. Packaging, etc.
• 9.3. By Manufacturing Type (USD)
  • 9.3.1. Continuous
  • 9.3.2. Batch
• 9.4. By End User (USD)
  • 9.4.1. Large Scale Pharmas
  • 9.4.2. CDMO
  • 9.4.3. CMO
  • 9.4.4. CRO
• 9.5. By Country (USD)
  • 9.5.1. China
    • 9.5.1.1. By End User
  • 9.5.2. India
    • 9.5.2.1. By End User
  • 9.5.3. Japan
    • 9.5.3.1. By End User
  • 9.5.4. South Korea
    • 9.5.4.1. By End User
  • 9.5.5. ASEAN
    • 9.5.5.1. By End User
  • 9.5.6. Rest of Asia Pacific

10. Middle East & Africa Pharmaceutical Manufacturing Equipment Market Size Estimates and Forecasts, By Segments, 2021-2034

• 10.1. Key Findings
• 10.2. By Equipment (USD)
  • 10.2.1. Mixing & Blending
  • 10.2.2. Milling
  • 10.2.3. Dryer & Granulators
  • 10.2.4. Extrusion
  • 10.2.5. Filling & Compression
  • 10.2.6. Inspection & Sterilization
  • 10.2.7. Packaging, etc.
• 10.3. By Manufacturing Type (USD)
  • 10.3.1. Continuous
  • 10.3.2. Batch
• 10.4. By End User (USD)
  • 10.4.1. Large Scale Pharmas
  • 10.4.2. CDMO
  • 10.4.3. CMO
  • 10.4.4. CRO
• 10.5. By Country (USD)
  • 10.5.1. South Africa
    • 10.5.1.1. By End User
  • 10.5.2. GCC
    • 10.5.2.1. By End User
  • 10.5.3. Rest of MEA

11. Company Profiles for Top 10 Players (Based on data availability in public domain and/or on paid databases)

• 11.1. GEA Group
  • 11.1.1. Overview
    • 11.1.1.1. Key Management
    • 11.1.1.2. Headquarters
    • 11.1.1.3. Offerings/Business Segments
  • 11.1.2. Key Details (Key details are consolidated data and not product/service specific)
    • 11.1.2.1. Employee Size
    • 11.1.2.2. Past and Current Revenue
    • 11.1.2.3. Geographical Share
    • 11.1.2.4. Business Segment Share
    • 11.1.2.5. Recent Developments
• 11.2. Romaco Group
  • 11.2.1. Overview
    • 11.2.1.1. Key Management
    • 11.2.1.2. Headquarters
    • 11.2.1.3. Offerings/Business Segments
  • 11.2.2. Key Details (Key details are consolidated data and not product/service specific)
    • 11.2.2.1. Employee Size
    • 11.2.2.2. Past and Current Revenue
    • 11.2.2.3. Geographical Share
    • 11.2.2.4. Business Segment Share
    • 11.2.2.5. Recent Developments
• 11.3. IMA Group
  • 11.3.1. Overview
    • 11.3.1.1. Key Management
    • 11.3.1.2. Headquarters
    • 11.3.1.3. Offerings/Business Segments
  • 11.3.2. Key Details (Key details are consolidated data and not product/service specific)
    • 11.3.2.1. Employee Size
    • 11.3.2.2. Past and Current Revenue
    • 11.3.2.3. Geographical Share
    • 11.3.2.4. Business Segment Share
    • 11.3.2.5. Recent Developments
• 11.4. Syntegon Technology
  • 11.4.1. Overview
    • 11.4.1.1. Key Management
    • 11.4.1.2. Headquarters
    • 11.4.1.3. Offerings/Business Segments
  • 11.4.2. Key Details (Key details are consolidated data and not product/service specific)
    • 11.4.2.1. Employee Size
    • 11.4.2.2. Past and Current Revenue
    • 11.4.2.3. Geographical Share
    • 11.4.2.4. Business Segment Share
    • 11.4.2.5. Recent Developments
• 11.5. Sartorius AG
  • 11.5.1. Overview
    • 11.5.1.1. Key Management
    • 11.5.1.2. Headquarters
    • 11.5.1.3. Offerings/Business Segments
  • 11.5.2. Key Details (Key details are consolidated data and not product/service specific)
    • 11.5.2.1. Employee Size
    • 11.5.2.2. Past and Current Revenue
    • 11.5.2.3. Geographical Share
    • 11.5.2.4. Business Segment Share
    • 11.5.2.5. Recent Developments
• 11.6. ACG Group
  • 11.6.1. Overview
    • 11.6.1.1. Key Management
    • 11.6.1.2. Headquarters
    • 11.6.1.3. Offerings/Business Segments
  • 11.6.2. Key Details (Key details are consolidated data and not product/service specific)
    • 11.6.2.1. Employee Size
    • 11.6.2.2. Past and Current Revenue
    • 11.6.2.3. Geographical Share
    • 11.6.2.4. Business Segment Share
    • 11.6.2.5. Recent Developments
• 11.7. Fette Compacting GmbH
  • 11.7.1. Overview
    • 11.7.1.1. Key Management
    • 11.7.1.2. Headquarters
    • 11.7.1.3. Offerings/Business Segments
  • 11.7.2. Key Details (Key details are consolidated data and not product/service specific)
    • 11.7.2.1. Employee Size
    • 11.7.2.2. Past and Current Revenue
    • 11.7.2.3. Geographical Share
    • 11.7.2.4. Business Segment Share
    • 11.7.2.5. Recent Developments
• 11.8. Glatt
  • 11.8.1. Overview
    • 11.8.1.1. Key Management
    • 11.8.1.2. Headquarters
    • 11.8.1.3. Offerings/Business Segments
  • 11.8.2. Key Details (Key details are consolidated data and not product/service specific)
    • 11.8.2.1. Employee Size
    • 11.8.2.2. Past and Current Revenue
    • 11.8.2.3. Geographical Share
    • 11.8.2.4. Business Segment Share
    • 11.8.2.5. Recent Developments
• 11.9. Paul Mueller Company
  • 11.9.1. Overview
    • 11.9.1.1. Key Management
    • 11.9.1.2. Headquarters
    • 11.9.1.3. Offerings/Business Segments
  • 11.9.2. Key Details (Key details are consolidated data and not product/service specific)
    • 11.9.2.1. Employee Size
    • 11.9.2.2. Past and Current Revenue
    • 11.9.2.3. Geographical Share
    • 11.9.2.4. Business Segment Share
    • 11.9.2.5. Recent Developments
• 11.10. SED Pharma
  • 11.10.1. Overview
    • 11.10.1.1. Key Management
    • 11.10.1.2. Headquarters
    • 11.10.1.3. Offerings/Business Segments
  • 11.10.2. Key Details (Key details are consolidated data and not product/service specific)
    • 11.10.2.1. Employee Size
    • 11.10.2.2. Past and Current Revenue
    • 11.10.2.3. Geographical Share
    • 11.10.2.4. Business Segment Share
    • 11.10.2.5. Recent Developments

12. Key Takeaways